Related parties - Details of relation with Gilead (Details) - Gilead [member] - EUR (€) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] | |||
| Trade and other receivables | € 3,833,000 | € 2,268,000 | € 5,198,000 |
| Trade and other payables | 585,000 | ||
| Revenue Recognized Related To The Performance Obligation For The Drug Discovery Platform | 1,068,967,000 | 230,182,000 | 230,242,000 |
| Revenue Recognised Related To Filgotinib Performance Obligation | 26,041,000 | 429,439,000 | |
| Royalty Income Related To The Commercialization Of Filgotinb | 12,177,000 | 10,604,000 | 9,466,000 |
| Cost Reimbursements Recognized Related To The Development Of GLPG1690 | 128,000 | 299,000 | |
| Cross charges from and to Gilead relating to filgotinib (4) | 36,000 | 3,643,000 | |
| Royalties Receivable | € 3,800,000 | € 2,200,000 | 2,400,000 |
| Filgotinib development cost sharing receivables. | € 2,500,000 | ||